PanAfrican Medical Journal

Annex 3: available information on immunohistochemistry record of breast cancer patients

Study sites	**Oestrogen receptor status**		**Progesterone receptor status**		**ER/PR/HER2 combinations**			
	ER+	**ER-**	**PR+**	**PR-**	**ER+PR+HER+**	**ER-PR-HER-**	**ER+PR+HER-**	**other**
	n (%)	**n (%)**	**n (%)**	**n (%)**	**n (%)**	**n (%)**	**n (%)**	**n (%)**
UATH	0 (50)	3 (100)	0 (0)	2 (100)	0 (0)	2(100)	0	0 (0)
LASUTH	8 (50)	8 (50)	8 (53.3)	7 (46.7)	5 (33.3)	5 (33.3)	3 (20)	2 (13.
NHA	35 (50.7)	34 (49.3)	33 (47.8)	36 (52.2)	6 (9.1)	18 (27.30)	20 (30.3)	22 (33
LUTH	22 (43.1)	29 (56.9)	16 (32.7)	33 (67.3)	8 (17)	24 (51.1)	8 (17)	7 (14.
GHLI	1 (50)	1 (50)	0 (0)	1 (100)	0(0)	1 (100)	0	0 (0)
TOTAL	66 (46.8)	75 (53.1)	57 (41.9)	79 (58.1)	19(14.6)	49 (37.8)	31 (23.8)	31 (23

ER+ =Oestrogen receptor positive; ER- =Oestrogen receptor negative; HER2 = *Human epidermal growth factor recept*
ER-PR-HER- = Triple negative; ER+PR+HER+ = Triple positive